Dr. Francesco Forconi on Questions That Remain Regarding Inhibiting the B-cell Receptor in CLL

Francesco Forconi, MD, associate professor of Hematology, University of Southampton, United Kingdom, discusses questions that remain regarding inhibiting the B-cell receptor (BCR) pathway for the treatment of patients with chronic lymphocytic leukemia (CLL).

Treatments such as idelalisib (Zydelig) and ibrutinib (Imbruvica), which inhibit the B-cell receptor (BCR) pathway, have shown success in the treatment of patients with CLL.

However, one question that remains is, why is the BCR variable, and can this variability be targeted therapeutically and more effectively, said Forconi.

While BCR-associated kinase inhibitors can be very effective therapeutic targets, they are not necessarily sufficient, he said.

There needs to be a better understanding of how B-cell signaling is influenced, what other pathways influence that, and how BCR-signaling inhibitors can be associated with other known genotoxic and chemotherapeutic agents.

Related Videos
Sujith Samarasinghe, MD
Suzanne Trudel, MSc, MD
Comparative Efficacy of Bruton Tyrosine Kinase Inhibitors in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia: A Network Meta-Analysis
Consuelo Bertossi, MD
Michael R. Grunwald, MD, FACP
Sundar Jagannath, MBBS
Kevin Kalinsky, MD, MS,
Aaron Gerds, MD
Paolo Tarantino, MD
Chinmay Jani, MD, clinical fellow, Hematology & Oncology, Sylvester Comprehensive Cancer Center at the University of Miami/Jackson Memorial Hospital